RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage
RegeneRx was recently allowed by the FDA to move into Phase III clinical trials with RGN-259 for the treatment of patients with NK.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
